Alexion Pharmaceuticals is a biopharmaceutical company focusing on the discovery, development, and commercialization of therapeutic products. These products aim to treat patients with severe and life-threatening diseases, including hematologic, kidney, and neurologic diseases, transplant rejection, cancer, and autoimmune disorders. The company's flagship product, Soliris (eculizumab), is an approved therapy for the treatment of patients with paroxysmal nocturnal hemoglobinuria (PNH). Alexion has been granted orphan drug designation for Soliris by both the United States Food and Drug Administration (FDA) and the European Commission (EC) for the treatment of patients with atypical Hemolytic Uremic Syndrome (aHUS).
Headquartered in Boston, Massachusetts, Alexion Pharmaceuticals has grown to employ over 2,500 workers from diverse demographic backgrounds since its beginning in 1992. Under the leadership of CEO Marc Dunoyer, the company has achieved a competitive annual revenue of $6.1 billion. Alexion’s commitment to innovation and its strong employee retention rate have helped establish their positive reputation, with staff members typically staying with the company for 4.3 years.
